Collectively, our findings underscore the tumor‐promoting function of the CDK4/6‐DUB3 axis in CRC through stabilizing YAP, suggesting that CDK4/6 inhibitors could be promising for CRC associated with aberrantly elevated DUB3 and YAP1. This evidence concerns the gene USP17L2 and colorectal carcinoma.